Michael Morris discusses integrating PSMA PET into high-risk biochemical recurrence, where systemic therapy follows the EMBARK regimen. Dr. Morris treats PSMA-avid oligoprogressive lesions with ...

Evaluating the Impact of Age on Prostate Cancer Overdiagnosis Using Long-Term Follow-Up From the CAP Randomised Trial - Beyond the Abstract ...

Transdermal Application of H100 Gel to the Penile Shaft in Patients with Peyronie's Disease Infiltrates the Tunica Albuginea - Beyond the Abstract ...

Comprehensive Analysis of microRNA Expression Provides Mechanistic Insights into Transcriptomic Alteration in Primary and Metastatic Testicular Germ Cell Tumors - Beyond the Abstract ...

The Kurt extraperitoneal ligamentopexy: A new surgical method with uterine preservation for pelvic organ prolapse, "Beyond the Abstract," by Sefa Kurt and Mehmet Tunc Canda ...

Multi-Institutional External Validation of the European Risk Classification for High-Grade Ta Non-Muscle-Invasive Bladder Cancer - Beyond the Abstract ...

Purine Nucleoside Phosphorylase as a Target for the Treatment of Interstitial Cystitis/Bladder Pain Syndrome with and without Hunner Lesions - Beyond the Abstract ...

Hashim Hashim joins Diane Newman for a conversation on the definitions of lower urinary tract dysfunction and the role and timing of urodynamics in the diagnosis of the specific condition. They also ...

(UroToday.com) The 2024 Southeastern Section of the AUA (SESAUA) annual meeting featured a bladder cancer session and a presentation by Dr. Shreyas Joshi discussing the prevalence, trends, and costs ...

(UroToday.com) The 2026 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Wolfgang Fendler discussing external validation of new prostate cancer risk groups by PSMA-PET.

The 2026 ProsTIC annual meeting featured a Lutetium-177 session and a presentation by Dr. Renu Eapen discussing whether there is a role for 177 Lu-PSMA-617 prior to or after surgery.

The Prostate Cancer Foundation framework summarizes five major components used for risk stratification: PSA level, tumor grade on biopsy, T stage, extent of disease including nodal or distant ...